News & Resources

Using Social Network Analysis to Identify Key Scientific Leaders

“Key opinion leader” (KOL) is a term most often used to refer to a medical partner, expert, or external advisor whose voice is highly respected within their specific therapeutic field. KOLs have become vital to the drug development process, and many pharmaceutical companies are seeking deeper collaborations with KOLs.

Findings from a 2015 online survey presented at the Medical Affairs Leaders Forum in Berlin, Germany, revealed that the majority of the senior medical community believe the term KOL is often inappropriately used for people who do not necessarily warrant the title. The term “key scientific leader” (KSL) may be an alternative to KOL.
The trend to engage KSLs during earlier stages—prior to clinical trials and commercialization—creates the need to identify KSLs with broad and current experiences in initial drug development, trial design, and more.

Because effective methods of identifying and engaging key scientific leaders are continually evolving, a provider of medical insights can offer life sciences companies many strategies to help guide them in a thoughtful partnership with KSLs. Traditional methods include searching literature databases and compiling surveys; however, these are limited and run the risk of “responder bias,” which is discussed later. In this blog, we’ll further explore new and different approaches to identifying KSLs through social network analysis (SNA).

What Is Social Network Analysis?
In SNA, interactions between thought leaders and experts in a given therapeutic field are tracked as relationships or connections that create a social network construct. Relationships are based on shared information and collaboration across different research communities and are assigned value, otherwise called social capital. The results of an SNA specifically examine the social structure of these networks and evaluate the position of the members within it.

A network, for example, could involve thousands of researchers and medical experts from around the world. In this case, SNA is used to capture the collaboration of participants in the network; these participants come from pharmaceutical companies, educational institutions, advisory boards, and regulatory bodies. Analysis of these collaborations can provide context and insight about how important one acting body is within the network hierarchy. Furthermore, a structural analysis of a network can project the cohesiveness of a group or collaboration.

How Is Social Network Analysis Used to Identify Key Scientific Leaders?
Techniques used to analyze and evaluate key players in a network generally measure communications and productivity. Data are collected from various sources and used to map the professional qualities of a thought leader. What are these data, exactly? Nodes, representing social network users or user groups, and ties, representing the relationships among users, are converted into quantifiable data. Nodes and ties attribute certain properties, eg, age or qualification of a person, or the strength of a relationship based on frequency of interaction. Based on the defined properties, the nodes or ties can be selectively extracted and a new network created.

Since the goals of the analysis can be tailored to the distinct requirements of a company, specific measures are then applied to the new network. Applications of SNA include the use of centrality measures, for example, that can identify the profiles of coauthors and author collaborations. In this case, the nodes are the authors and the collaborations are the ties. Thus, a social network based on “author collaboration” is born.

Each company has a different reason to identify thought leaders. For example, some pharmaceutical companies seek key scientific leaders with clinical experience in certain disease areas or research experience. Identifying the appropriate thought leader for an effective partnership should consider the company’s objectives; a KSL may be selected based on their experience and reputation, which considers factors like the number of publications, media presence, or seminar leadership. All of these can be determined by the properties used to define a network, as well as the measures applied to the network itself.

What Are the Benefits of Social Network Analysis?
As mentioned, SNA can be tailored to the needs of a company or product, specifically by defining the properties of a social network and the types of measures applied to it. Another key benefit of SNA is its scalability, meaning the approach to analyzing the network relationships can be applied to an entire community, or to a sample group of members. This can benefit a company if it is looking for a KSL whose expertise is specific to a focused area of research.

Furthermore, the general methodology behind SNA eliminates the responder bias—that which influences a participant’s response away from a truthful or accurate response—that is frequently associated with observation and survey methods used in traditional approaches to identifying KSLs. Social network analysis can demonstrate a KSL’s influence using facts derived from measurable data instead of personal opinions or referrals. While a thought leader’s publication history and their reputation as a key speaker on medical issues are still highly regarded, there are also forward-thinking individuals who fly under the radar. This is especially true for younger researchers, physicians focused on rare or recently discovered diseases, or those working on innovative treatment modalities, who may frequently offer a substantially better position in forming strategic KSL partnerships.

The value of social network analysis to identify key scientific leaders is demonstrated in its quick adoption by the medical sectors beyond pharma. Smaller companies, medical device manufacturers, and numerous other industries are using SNA methodology to provide insight into identifying the leading experts in a certain field. In turn, proper KSL identification can effectively influence an efficient path to market access. Beyond this goal, finding the right scientific leaders can help companies strategically develop their product and brand, or direct innovative research activities.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.
Aptitude Health
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.